

Tomas Kalincik

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8989830/tomas-kalincik-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

143
papers

3,390
citations

32
h-index

54
g-index

162
ext. papers

4,403
ext. citations

6
avg. IF

5.25
L-index

#	Paper	IF	Citations
143	Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103389	4	1
142	Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 58, 103404	4	0
141	Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive tests.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 58, 103393	4	0
140	Multiple Sclerosis Relapses Following Cessation of Fingolimod.. <i>Clinical Drug Investigation</i> , 2022 , 42, 3553.2		1
139	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221084577	5	0
138	The dynamics of relapses during treatment switch in relapsing-remitting multiple sclerosis.. <i>Journal of Theoretical Biology</i> , 2022 , 541, 111091	2.3	
137	Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy.. <i>Leukemia and Lymphoma</i> , 2022 , 1-11	1.9	0
136	A comparison of macular ganglion cell and retinal nerve fibre layer optical coherence tomographic parameters as predictors of visual outcomes of surgery for pituitary tumours.. <i>Pituitary</i> , 2022 , 1	4.3	0
135	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021 , 96, e783-e797	6.5	18
134	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2001-2013	5	2
133	Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study). <i>JMIR Research Protocols</i> , 2021 , 10, e24969	2	2
132	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211049986	5	2
131	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. <i>Neurology</i> , 2021 , 97, e1870-e1885	6.5	50
130	Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. <i>Neurology</i> , 2021 , 96, e214-e2276.5		2
129	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	3
128	Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis. <i>Journal of Neuroimmunology</i> , 2021 , 353, 577508	3.5	0
127	Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021 ,	6.5	8

126	Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study. <i>CNS Drugs</i> , 2021 , 35, 907-918	6.7	5
125	Lesser-Known Aspects of Deep Brain Stimulation for Parkinson's Disease: Programming Sessions, Hardware Surgeries, Residential Care Admissions, and Deaths. <i>Neuromodulation</i> , 2021 ,	3.1	2
124	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021 , 97, e869-e880	6.5	3
123	Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018. <i>CNS Drugs</i> , 2021 , 35, 1097-1106	6.7	3
122	The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities and neuropsychiatric symptoms. <i>International Journal of Neuroscience</i> , 2021 , 131, 800-809	2	5
121	Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 465-474	5	10
120	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 755-766	5	3
119	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 695-705	5	4
118	Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 47, 102642	4	6
117	Comparative effectiveness of rituximab in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2021 , 17, 3-4	15	2
116	The prevalence of epileptic seizures in multiple sclerosis in a large tertiary hospital in Australia. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 2055217321989767	2	0
115	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. <i>NeuroImage: Clinical</i> , 2021 , 32, 102802	5.3	0
114	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1838-1851	5	2
113	Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 556-562	5.5	4
112	Adverse events related to antiepileptic drugs. <i>Epilepsy and Behavior</i> , 2021 , 115, 107657	3.2	1
111	The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211035948	5	1
110	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103012	4	3
109	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. <i>Journal of Neuroimmunology</i> , 2021 , 357, 577627	3.5	8

108	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021 , 208, 106180	6.9	2
107	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021 , 35, 1217-1232	6.7	1
106	Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , 2021 , 97, e2020-e2031	6.5	0
105	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021 , 430, 118067	3.2	0
104	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.. <i>Pharmacoeconomics</i> , 2021 , 40, 323	4.4	
103	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020 , 143, 1400-1413	11.2	13
102	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520925369	5	14
101	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , 2020 , 19, 307-316	24.1	77
100	The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 43, 102212	4	
99	Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the ACTION-MS trial): protocol of an assessor-blinded, active comparator, randomised controlled trial. <i>Trials</i> , 2020 , 21, 100	2.8	2
98	Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. <i>Neurology: Clinical Practice</i> , 2020 , 10, 510-519	1.7	13
97	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1765-1774	5	5
96	Psychometric properties of the Hospital Anxiety and Depression Scale in an inpatient video-monitoring epilepsy cohort. <i>Epilepsy and Behavior</i> , 2020 , 103, 106631	3.2	4
95	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101868	4	15
94	Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102516	4	5
93	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. <i>JAMA Neurology</i> , 2020 , 77, 1496-1503	17.2	11
92	COVID-19 in people with multiple sclerosis: A global data sharing initiative. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1157-1162	5	34
91	A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia. <i>BMJ Open</i> , 2020 , 10, e040100	3	3

90	Reply: Aggressive multiple sclerosis: a matter of measurement and timing. <i>Brain</i> , 2020 , 143, e98	11.2	
89	Presentation and outcome of patients with intracranial tuberculoma in a high HIV prevalence setting. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020 , 24, 224-232	2.1	3
88	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020 , 77, 1398-1407	17.2	8
87	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020 , 143, 2742-2756	11.2	8
86	Serum microRNA is a biomarker for post-operative monitoring in glioma. <i>Journal of Neuro-Oncology</i> , 2020 , 149, 391-400	4.8	13
85	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 79-90	5	27
84	Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 159-161	5	1
83	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	16
82	The MSBase registry: Informing clinical practice. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1828-1834	5	19
81	The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286419859183	6.6	8
80	Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. <i>Lancet Neurology</i> , 2019 , 18, 973-980	24.1	49
79	Head-to-head drug comparisons in multiple sclerosis: Urgent action needed. <i>Neurology</i> , 2019 , 93, 793-809	5	13
78	Personality profiles differ between patients with epileptic seizures and patients with psychogenic non-epileptic seizures. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2019 , 73, 1-8	3.2	6
77	Abbreviated assessment of psychopathology in patients with suspected seizure disorders. <i>Epilepsy and Behavior</i> , 2019 , 100, 106530	3.2	2
76	131 CLADIN: CLADribine and INnate immune responses. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, A42.3-A42	5.5	
75	020 Increased risk of an abnormal cervical screening test in women with MS exposed to high-efficacy disease-modifying treatments. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, A7.3-A7	5.5	0
74	PACS Integration of Semiautomated Imaging Software Improves Day-to-Day MS Disease Activity Detection. <i>American Journal of Neuroradiology</i> , 2019 , 40, 1624-1629	4.4	2
73	Distinct psychopathology profiles in patients with epileptic seizures compared to non-epileptic psychogenic seizures. <i>Epilepsy Research</i> , 2019 , 158, 106234	3	8

72	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 458-468	5.5	46
71	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 28, 235-243	4	22
70	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 175-187	27.4	172
69	Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy. <i>Journal of Neurology</i> , 2019 , 266, 306-315	5.5	9
68	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019 , 26, 363-370	6	8
67	Reply: Towards personalized therapy for multiple sclerosis: limitations of observational data. <i>Brain</i> , 2018 , 141, e39	11.2	1
66	Cognitive clinico-radiological paradox in early stages of multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 81-91	5.3	17
65	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 642-652	5	18
64	Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1617-1626	5	21
63	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018 , 75, 1407-1415	17.2	13
62	Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1569-1577	5	3
61	Where there is inflammation, treatment may reduce disability progression - Yes. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1808-1810	5	2
60	Reporting treatment outcomes in observational data: A fine balance. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 21-22	5	7
59	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 51-61	5	31
58	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 266-276	5	22
57	Treatment decisions in multiple sclerosis - insights from real-world observational studies. <i>Nature Reviews Neurology</i> , 2017 , 13, 105-118	15	126
56	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 196-203	5.5	43
55	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , 2017 , 16, 271-281	24.1	101

54	Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. <i>Autoimmunity Reviews</i> , 2017 , 16, 658-665	13.6	76
53	Familial mesial temporal lobe epilepsy and the borderland of dJlvu. <i>Annals of Neurology</i> , 2017 , 82, 166-176	6.4	12
52	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017 , 89, 1050-1059	6.5	31
51	Data quality evaluation for observational multiple sclerosis registries. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 647-655	5	43
50	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1346-1357	5	13
49	Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach. <i>European Journal of Neurology</i> , 2017 , 24, 292-301	6	20
48	The impact of location, time and practice effects on computerised cognitive testing using msreactor in people with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, e1.3-e1	5.5	
47	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017 , 140, 2426-2443	11.2	62
46	Stop inflammation and you stop neurodegeneration in MS - NO. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1321-1323	11.2	11
45	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 520-32	5	30
44	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016 , 80, 89-100	9.4	117
43	Observational data: Understanding the real MS world. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1642-1648	5	56
42	Impairment of Smooth Pursuit as a Marker of Early Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2016 , 7, 206	4.1	10
41	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016 , 139, 2395-405	11.2	172
40	Comparative efficacy of first-line natalizumab vs IFN- β or glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016 , 6, 102-115	1.7	21
39	Olfactory ensheathing cells but not fibroblasts reduce the duration of autonomic dysreflexia in spinal cord injured rats. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2016 , 201, 17-23	2.4	8
38	Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β 1a. <i>European Journal of Neurology</i> , 2015 , 22, 1113-23	6	22
37	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 479-91	5.3	36

36	Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. <i>JAMA Neurology</i> , 2015 , 72, 405-13	17.2	83
35	Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis. <i>European Journal of Neurology</i> , 2015 , 22, 624-32	6	11
34	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015 , 138, 3287-98	11.2	107
33	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1159-71	5	30
32	Comparative efficacy of switching to natalizumab in active multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 373-87	5.3	42
31	Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review. <i>Neuroepidemiology</i> , 2015 , 44, 199-214	5.4	79
30	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015 , 77, 425-35	9.4	118
29	Fingolimod after natalizumab and the risk of short-term relapse. <i>Neurology</i> , 2014 , 82, 1204-11	6.5	113
28	Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. <i>Journal of Neurology</i> , 2014 , 261, 1735-44	5.5	38
27	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1511-22	5	49
26	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013 , 136, 3609-17	11.2	96
25	Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome. <i>Genes and Immunity</i> , 2013 , 14, 244-8	4.4	14
24	Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. <i>PLoS ONE</i> , 2013 , 8, e63480	3.7	22
23	Thalamic atrophy is associated with development of clinically definite multiple sclerosis. <i>Radiology</i> , 2013 , 268, 831-41	20.5	119
22	Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. <i>American Journal of Neuroradiology</i> , 2013 , 34, 1931-9	4.4	68
21	Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. <i>PLoS ONE</i> , 2013 , 8, e53996	3.7	50
20	Early predictors of non-response to interferon in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2012 , 126, 390-7	3.8	21
19	Clinical correlates of grey matter pathology in multiple sclerosis. <i>BMC Neurology</i> , 2012 , 12, 10	3.1	41

18	Cost of multiple sclerosis in the Czech Republic: the COMS study. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 662-8	5	32
17	Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. <i>Clinical Neurology and Neurosurgery</i> , 2012 , 114, 940-6	2	16
16	Disturbance of real space navigation in moderately advanced but not in early Huntington's disease. <i>Journal of the Neurological Sciences</i> , 2012 , 312, 86-91	3.2	19
15	Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). <i>Clinical Neuropsychologist</i> , 2012 , 26, 1186-200	4.4	88
14	Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study. <i>European Neurology</i> , 2012 , 68, 23-7	2.1	26
13	Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. <i>PLoS ONE</i> , 2012 , 7, e50101	3.7	62
12	Interferon- β or azathioprine as add-on therapies in patients with active multiple sclerosis. <i>Neurological Research</i> , 2012 , 34, 923-30	2.7	7
11	Heparinase-modified thromboelastography can result in a fibrinolytic pattern. <i>Anaesthesia</i> , 2010 , 65, 864-5	6.6	8
10	Arteriovenous differences of hematological and coagulation parameters in patients with sepsis. <i>Blood Coagulation and Fibrinolysis</i> , 2010 , 21, 770-4	1	7
9	Olfactory ensheathing cells reduce duration of autonomic dysreflexia in rats with high spinal cord injury. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2010 , 154, 20-9	2.4	23
8	Selected changes in spinal cord morphology after T4 transection and olfactory ensheathing cell transplantation. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2010 , 158, 31-8	2.4	11
7	Discard volume necessary for elimination of heparin flush effect on thromboelastography. <i>Blood Coagulation and Fibrinolysis</i> , 2010 , 21, 192-5	1	7
6	Local response to cold in rat tail after spinal cord transection. <i>Journal of Applied Physiology</i> , 2009 , 106, 1976-85	3.7	9
5	Influence of magnesium sulphate on evoked activity of rat brain after exposure to short-term hypoxia. <i>Physiological Research</i> , 2005 , 54, 229-34	2.1	2
4	Early clinical markers of aggressive multiple sclerosis		1
3	The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities, and neuropsychiatric symptoms		1
2	Immunotherapy prevents long-term disability in relapsing multiple sclerosis over 15 years		1
1	Associations of DMT therapies with COVID-19 severity in multiple sclerosis		20

